<DOC>
	<DOCNO>NCT00512681</DOCNO>
	<brief_summary>Patients treat irinotecan ( 150mg/m2 ) follow oxaliplatin ( 85mg/m2 ) day 1 S-1 ( 80mg/m2/day ) day 1 14 every 3 week . Patients receive plan treatment maximum 12 cycle chemotherapy . Response assessement perform every 2 cycle chemotherapy .</brief_summary>
	<brief_title>A Phase II Study Irinotecan , Oxaliplatin , Plus TS-1 Untreated Metastatic Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>1 . Histologically cytologically confirm gastric adenocarcinoma recurrent metastatic disease 2 . Age ≥18 year 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 4 . Disease status must measurable disease define RECIST criterion : Measurable lesion : Lesions accurately measure least one dimension following : CT abdomen , pelvis thorax , long diameter record least 10 mm spiral CT Chest xray , lung lesion record clearly define surround aerated lung diameter record least 20 mm Physical examination , clinically detect lesion superficial ( e.g. , skin nodule palpable lymph node ) least 10 mm 5 . No prior treatment recurrent metastatic disease ; prior adjuvant/neoadjuvant therapy allow least 12 month elapse completion adjuvant/neoadjuvant therapy enrolment study . However , prior oxaliplatin and/or irinotecan adjuvant therapy allow . 6 . Adequate major organ function include follow : Hematopoietic function : ANC ³ 1,500/mm3 , Platelet ³ 100,000/mm3Hepatic function : serum bilirubin 1.5 mg/dl , AST/ALT level 2.5 x UNL ( 5 x UNL liver metastasis present ) Renal function : serum creatinine UNL 7 . Patients sign write informed consent study entry 1 . Prior history peripheral neuropathy 2 . Inadequate cardiovascular function : New York Heart Association class III IV heart diseaseUnstable angina myocardial infarction within past 6 monthsHistory significant ventricular arrhythmia require medication antiarrhythmic significant conduction system abnormality 3 . Serious concurrent infection nonmalignant illness uncontrolled whose control may jeopardize complication study therapy 4 . Other malignancy within past 3 year except nonmelanomatous skin cancer carcinoma situ cervix 5 . Psychiatric disorder would preclude compliance 6 . Pregnant , nursing woman patient reproductive potential without contraception 7 . Patients receive concomitant treatment drug interact S1 flucytosine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Stomach Neoplasms</keyword>
	<keyword>Secondary</keyword>
	<keyword>Combination chemotherapy</keyword>
	<keyword>S-1</keyword>
	<keyword>irinotecan</keyword>
	<keyword>oxaliplatin</keyword>
</DOC>